India-based healthcare and life sciences technology provider and consultant CitiusTech has claimed to come up with what could be the industry's first generative AI quality and trust solution. 

Based on a press statement, the CitiusTech Gen AI Quality & Trust solution aims to help with the design, development, integration, monitoring of, and facilitating quality and trust in genAI applications in healthcare.

Utilising an automated design and decision-making framework, the software-based solution will provide "pre-packaged measures, automated output validation and monitoring" of the quality and trustworthiness of gen AI solutions. It features over 70 metrics and more than 25 methods across seven dimensions – Accuracy, Calibration, Robustness, Fairness, Bias, Toxicity and Efficiency. 

CitiusTech says their software offering fully integrates into existing MLOps, DataOps and quality management solutions.

WHY IT MATTERS

"Our Gen AI Quality & Trust Solution is the first systematic approach in healthcare to quantitatively measure, verify, and monitor genAI solutions," claimed Sridhar Turaga, CitiusTech's SVP of Data and Analytics. Until this day, he noted, "there are no established technology or platform-agnostic solutions that measure quality and trust of healthcare genAI solutions, end-to-end."

CitiusTech also claims that over 80% of genAI proofs of concept and initiatives which their clients conduct get delayed due to reliability and compliance concerns and lack of trust. 

"We are integrating this capability seamlessly into all our solutions and projects, ensuring our clients can confidently benefit from scaling genAI-powered solutions," added CEO Rajan Kohli. 

THE LARGER TREND

The pace of genAI adoption in healthcare – at least in Asia-Pacific, is expected to go slow this year as potential users remain on the fence regarding its safety and effectiveness. 

"We’ll see the most caution with anything that directly impacts patient care. We know technology can improve healthcare but if it doesn’t function as expected, it can slow down health systems, cost money, and consumer loyalty, and worst of all, impact patient outcomes," Kota Kubo, CEO of Ubie, previously told MobiHealth News. The Japanese IT startup has recently integrated genAI into a new feature on its patient service platform, Ubie Medical Navi. 

A recent noteworthy adoption of genAI in the region is China Medical University Hospital in Taiwan, which is now leveraging Google Cloud's MedLM to develop assistive tools for precision cancer treatment. In Singapore, national health tech agency Synapxe is currently collaborating with Microsoft to build a GPT-based platform using Azure OpenAI Service to support the development of large language model-based apps. Singapore General Hospital has also shared its intention to leverage genAI to enhance the capabilities of its predictive tool CARES-ML for pre-surgery assessment.